2018 ASH Congress: the Annual Unmissable Event for CALYM Researchers

CALYM researchers will present their last research results on lymphoma. Four oral communications and thirteen posters were indeed selected.

The oral communications are:

• “A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B‐Cell Lymphoma in Need of Systemic Therapy.” F Morschhauser et al. (Session 622, 3/12/18 at 3:30 pm, San Diego Convention Center, Room 28D)
• “Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1‐2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials.” C Laurent et al. (Session 624. 3/12/18 at 6:45 pm, San Diego Convention Center, Room 6F)
• “Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T‐Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 LYSA Study.” F Lemonnier et al. (Session 624. 3/12/18 at 6:45 pm, San Diego Convention Center, Room 6F)
• “Desynchronization of the Germinal Center dynamics and remodeling of the tumor microenvironment characterize Kmt2d-driven lymphomagenesis.” G Brisou et al. (Session 621, 3/12/18 at 11:15 am, San Diego Convention Center, Room 28D)

The posters are:

• “Breast Implant Associated‐Anaplastic Large Cell Lymphoma (BIA‐ALCL): The French Lymphoma Study Association (LYSA) Registry Data.” F Le Bras et al.
• “Superiority of Allogenic Stem Cell Transplantation after Anti‐PD1 Therapy over Anti‐PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program.” G Manson et al.
• “Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma‐Genomic Project Conducted on Behalf of the LYSA Group.” Y Le Bris et al.
• “Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno‐Chemotherapy ‐ a Study By the LYSA Group.” Y Le Bris et al.
• “Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study.” AS Cottereau et al.
• “Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the LYSA EORTC 20012 Randomized Protocol.” D Canioni et al.
• “Results from a Phase Ib Evaluation of Tazemetostat (EPZ‐6438) in Combination with RCHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a LYSA Study.” C Sarkozy et al.
• “BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers.” H Ghesquières et al.
• “Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial.” S Le Gouil et al.
• “Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA.” P Vandenberghe et al.
• “CSF1R and BTK Inhibitions as Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages.” A Papin et al.
• “Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin.” PE Debureaux et al.
• “Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and LYSA Study on Circulating Cell Free DNA.” L Buedts et al.

More information